Diagnosing Sanofi’s COVID-19 vaccine portfolio
26/06/20 -"Sanofi is developing a COVID-19 vaccine based on the traditional/proven recombinant-platform technology. It has the capability to manufacture 1bn doses by the end of 2021. Also, the French firm has ..."
Pages
79
Language
English
Published on
26/06/20
You may also be interested by these reports :
09/07/20
A couple of months after our last teaser (FAES FARMA’S DREAM RUN OVER?) in October 2019, Faes Farma (Reduce, Spain) touched a new lifetime high – led ...
08/07/20
Following our headline ’Settled!?’ on 25/06/2020, our new headline looks a bit revanchist as we had expected that Bayer ‘just’ wanted to manage ...
03/07/20
With CHF13bn ($14bn) annual sales, Roche is a dominant force in the global diagnostics market. Interestingly, in recent years, most diagnostics ...
03/07/20
With increasing demand for Roche’s COVID-19 tests – particularly molecular tests, the annual top-line should benefit by CHF1.5bn. Moreover, taking ...